Q: Has Methotrexate 10mg/5ml oral solution been removed from the Specials Tariff?
A: Yes. Methotrexate solution was previously listed in Part VIIIB (Specials) of the England and Wales Drug Tariff .
The strength of the oral solution is now available as licensed proprietary product manufactured by Rosemont Pharmaceuticals. It has therefore been relisted in part VIIIA of the England and Wales Tariff as Category C with a set reimbursement price and is listed in two pack sizes.
Methotrexate oral suspension remains available as an unlicensed special but should not be prescribed where a licensed alternative exists i.e. the oral solution. For this reason Methotrexate oral suspensions have been removed from the list of approved specials in Part VIIIB (Specials).
Prescriptions for the oral suspension can be ordered and endorsed as a non-Part VIIIB special, however best practice dictates that the prescriber is informed of the availability of the licensed oral solution.
The oral suspensions and solutions are not listed in the Scotland Tariff at the time of writing.
There is no specials tariff in Northern Ireland and contractors should endorse prescriptions to reflect the cost of the product dispensed.
|Drug Tariff Listing||Drug Tariff Part||Scotland Tariff||Manufacturer|
|Methotrexate 2mg/ml oral solution 35ml*||Part VIIIA Cat C||No listing. Endorse: packsize, manufacturer, price, QTY||Rosemont Pharmaceuticals Ltd|
|Methotrexate 2mg/ml oral solution 65ml*||Part VIIIA Cat C||No listing. Endorse: packsize, manufacturer, price, QTY||Rosemont Pharmaceuticals Ltd|
Each week we will be highlighting a popular question or issue addressed by our information services team to help keep you informed about the hot topics being discussed by other members.
If you have any questions about the Drug Tariff - send Sue a message or call Information Services on 0800 783 5709